AC Immune SA - Company Profile
Powered by 
All the data and insights you need on AC Immune SA in one report.
$295
- Save hours of research time and resources with
our up-to-date AC Immune SA Strategy Report
- Understand AC Immune SA position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
AC Immune SA (AC Immune) is a clinical-stage biopharmaceutical company that discovers, designs and develops proprietary medicines to prevent, diagnose and treat neurodegenerative diseases associated with protein misfolding. The company develops drugs based on its two proprietary technology platforms: SupraAntigen and Morphomer. Its technology platforms help the company to design, discover and develop antibodies, small molecules and vaccines. AC Immune’s product pipeline includes nine therapeutic product candidates and three diagnostic product candidates. The company’s lead product candidate crenezumab, is a monoclonal antibody that targets abeta in cognitive healthy individuals who are at risk of developing familial Alzheimer’s Disease (fAD). AC Immune is headquartered in Lausanne, Switzerland.
Headquarters
Switzerland
Address
Epfl Innovation Park, Building B, Lausanne, 1015
Website
www.acimmune.com
Telephone
41 21 3459121
No of Employees
133
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
ACIU (NASD)
Revenue (2022)
$16.5M
276.1%
(2022 vs 2021)
EPS
XYZ
Net Income (2022)
XYZ
23.3%
(2022 vs 2021)
Market Cap*
$235.1M
Net Profit Margin (2022)
XYZ
79.6%
(2022 vs 2021)
* As of and is in US$
AC Immune SA premium industry data and analytics
Products and Services
| Products |
|---|
| Pipeline |
| Crenezumab (anti-Abeta antibody)- Alzheimer’s Disease |
| ACI-24 (anti-Abeta vaccine)- Alzheimer’s Disease |
| XYZ |
| XYZ |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2023 | Regulatory Approval | In June, the company received FDA fast track designation for anti-amyloid-beta active immunotherapy, ACI-24.060, to treat Alzheimer’s disease. |
| 2022 | Corporate Changes/Expansions | In October, the company opened new centers in phase 1b/2 trial evaluating ACI-24 targeting Abeta In Alzheimer’s disease and down yyndrome. |
| 2021 | Acquisitions/Mergers/Takeovers | In July, the company announced the acquisition of AFFiRiS’ anti-alpha-synuclein programs. |
Competitor Comparison
| Key Parameters | AC Immune SA | Tillotts Pharma AG | Idorsia Pharmaceutical Ltd | Addex Therapeutics Ltd | Pharnext SA |
|---|---|---|---|---|---|
| Headquarters | Switzerland | Switzerland | Switzerland | Switzerland | France |
| City | Lausanne | Rheinfelden | Allschwil | Plan-Les-Ouates | Suresnes |
| State/Province | - | Aargau | - | - | Ile-de-France |
| No. of Employees | 133 | 373 | 1,361 | 22 | 44 |
| Entity Type | Public | Private | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Douglas E. Williams, Ph.D. | Chairman | Executive Board | - | 64 |
| Andrea Pfeifer, Ph.D. | Chief Executive Officer; Director | Executive Board | 2016 | 65 |
| Christopher Roberts | Chief Financial Officer | Senior Management | 2022 | 34 |
| Jean-Fabien Monin | Chief Administrative Officer | Senior Management | 2015 | 52 |
| Johannes R. Streffer | Chief Medical Officer | Senior Management | 2021 | 54 |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer